GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Circio Holding ASA (OSL:CRNA) » Definitions » Debt-to-Revenue

Circio Holding ASA (OSL:CRNA) Debt-to-Revenue : N/A (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Circio Holding ASA Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Circio Holding ASA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr110.65 Mil. Circio Holding ASA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr0.00 Mil. Circio Holding ASA's annualized Revenue for the quarter that ended in Dec. 2023 was kr0.00 Mil.


Circio Holding ASA Debt-to-Revenue Historical Data

The historical data trend for Circio Holding ASA's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Circio Holding ASA Debt-to-Revenue Chart

Circio Holding ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.85 103.99 N/A 6.34 899.62

Circio Holding ASA Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A 1.59 N/A N/A

Competitive Comparison of Circio Holding ASA's Debt-to-Revenue

For the Biotechnology subindustry, Circio Holding ASA's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Circio Holding ASA's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Circio Holding ASA's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Circio Holding ASA's Debt-to-Revenue falls into.



Circio Holding ASA Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Circio Holding ASA's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(110.653 + 0) / 0.123
=899.62

Circio Holding ASA's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(110.653 + 0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Circio Holding ASA Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Circio Holding ASA's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Circio Holding ASA (OSL:CRNA) Business Description

Traded in Other Exchanges
Address
Vollsveien 19, Lysaker, Oslo, NOR, 1366
Circio Holding ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer. It includes the development and implementation with the purpose of developing targeted immunotherapy treatments for cancer patients.

Circio Holding ASA (OSL:CRNA) Headlines

No Headlines